MBOAT7 and digestive system neoplasm: Although these compounds require further characterization and optimization, they provide a foundation for developing selective MBOAT7 inhibitors as therapeutic agents for aggressive cancers with MBOAT7 dependency, where their use may be valuable despite potential adverse effects such as causing transient fatty liver.